17321-20-9

Basic information

• Product Name: 3-CHLORO-6-ETHOXYPYRIDAZINE
• Synonyms: 3-CHLORO-6-ETHOXYPYRIDAZINE;3-chloro-6-ethoxypyridazine(SALTDATA: FREE);NSC 94042;Pyridazine, 3-chloro-6-ethoxy-
• CAS NO: 17321-20-9
• Molecular Formula: C₆H₇ClN₂O
• Molecular Weight: 158.58558
• Mol File: 17321-20-9.mol

Chemical Properties

• Melting Point: 60-62℃
• Boiling Point: 293.1°Cat760mmHg
• Flash Point: 131.1°C
• Appearance: /
• Density: 1.235
• Vapor Pressure: 0.00308mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.82±0.10(Predicted)
• CAS DataBase Reference: 3-CHLORO-6-ETHOXYPYRIDAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-6-ETHOXYPYRIDAZINE(17321-20-9)
• EPA Substance Registry System: 3-CHLORO-6-ETHOXYPYRIDAZINE(17321-20-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 17321-20-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
3-Chloro-6-Ethoxypyridazine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block in the development of new drugs, potentially leading to the creation of novel therapeutic agents.
Used in Chemical Research:
In the field of chemical research, 3-Chloro-6-Ethoxypyridazine is used as a model compound to study the properties and reactivity of pyridazine derivatives. This helps researchers understand the behavior of similar compounds and develop new synthetic strategies or applications.
Used in Industrial Applications:
3-Chloro-6-Ethoxypyridazine may also find use in various industrial applications, where its unique structure and properties can be harnessed for the development of new materials or processes. 3-CHLORO-6-ETHOXYPYRIDAZINE's potential in these areas is currently being explored, with the aim of identifying its most effective uses.

InChI:InChI=1/C6H7ClN2O/c1-2-10-6-4-3-5(7)8-9-6/h3-4H,2H2,1H3

Upstream product

• 141-30-0 3,6-dichlorpyridazine 
• 141-52-6 sodium ethanolate 
• 64-17-5 ethanol 

Downstream Products

• 748141-86-8 1-[6-(ethyloxy)pyrazolo[1,5-b]pyridazin-3-yl]ethanone 
• 62567-44-6 3-(ethyloxy)pyridazine 
• 19064-67-6 6-chloro-2H-pyridazin-3-one 

Relevant articles and documents

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Selective mono-amination of dichlorodiazines

A mild, easy-to-perform, and versatile method for the formation of aminochlorodiazines from reaction of several types of dichlorodiazines (i.e., pyridazines, pyrimidines, and pyrazines) with primary or secondary amines in ethanol in the presence of trieth

N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy

Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.

The Mechanism of Thermal Eliminations. Part 18. Relative Rates of Pyrolysis of 2-Ethoxypyrazine, 3-Ethoxypyridazine, 2-and 4-Ethoxypyrimidine, 3-Chloro-6-ethoxypyridazine, and 2-Chloro-4-ethoxypyrimidine : the Effect of the Aza 'Substituent' and ?-Bond Order on the Elimination Rate

A kinetic study has been made of the first-order thermal decomposition of the title compounds into ethylene and the corresponding aza-substituted pyridines, between 650 and 713 K.The relative elimination rates at 650 K are (2-ethoxypyridine = 1): 0.545, 10.0, 1.03, 1.12, 9.68, and 3.28, respectively.The electronic effects of the aza 'substituent' are small, and a more important factor appears to be the C-N ?-bond order; this latter accounts for the high reactivity of the pyridazines.The effects of the chloro substituent and of the aza 'substituent' are explicable in terms of a balance between electron withdrawal from the C-O bond (producing deactivation) and from the nitrogen involved in the cyclic transition state (producing deactivation).The effects of the chloro substituents confirm that the most important step of the reaction is breaking of the C-O bond.The statistically corrected rate (per ring nitrogen) of 2-ethoxypyrimidine is unexpectedly low.This may reflect difficulty in achieving the coplanar transition state in which the lone pairs in the s-orbitals of oxygen and the nitrogen not involved in the elimination are brought into close proximity.

Quinoxaline studies. 23. Potential antimalarials. Substituted 5,8-dimethoxy-6-[N-(omega-dimethylaminoalkyl)amino]quinoxalines were prepared: the first series with identical 2,3-substituents H, CH3, C6H5, C6H4-4-Cl, and CH2C6H5; and the second with identical styryl groups CH=CHC6H5, CH=CHC6H4-4-Cl, CH=CHC6H3-3,4-Cl2, CH=CHC6H4-4-F, CH=CHC6H4-4-CF3, and CH=CHC6H4-4-NO2. None of the substances

3-Hydrazinopyridazines substituted in position 6 with a primary amine, secondary amine, or an alkoxy group were synthesized and screened for antihypertensive activity. In general, the 6-dialklamino derivatives are the most active; the (2-hydroxypropyl)methylamino chain provides the best combination of high antihypertensive activity and toxicity.